Cytochrome P450 variations in different ethnic populations

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 3, 2012, Pages 371-382

  McGraw, Joseph ^a   Waller, Donald ^b  

^a Department of Pharmaceutical Sciences   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

African American; CYP450; Drug; Ethnicity; Genotype; Phenotype; Polymorphism; Race; Xenobiotic

Indexed keywords

AFLATOXIN; AMFEBUTAMONE; CHLORZOXAZONE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DESIPRAMINE; DEXTROMETHORPHAN; DICLOFENAC; ISOPROTEIN; LEFLUNOMIDE; LOSARTAN; MELATONIN; MEPHENYTOIN; METOPROLOL; MIDAZOLAM; OLANZAPINE; OMEPRAZOLE; PACLITAXEL; RILUZOLE; SIMVASTATIN; TACROLIMUS; TAMOXIFEN; THEOPHYLLINE; TOLBUTAMIDE; WARFARIN;

AFRICAN AMERICAN; AMERICAN INDIAN; CHROMOSOME 10Q; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; JAPANESE; LIVER BLOOD FLOW; LIVER CELL; LIVER MICROSOME; PHARMACOGENETICS; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; XENOBIOTIC METABOLISM;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; GENE FREQUENCY; GENOTYPE; HUMANS; LIVER; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; XENOBIOTICS;

EID: 84857273073     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.657626     Document Type: Review

References (88)

1. Clayman CB, Arnold J, Hockwald RS, et al. Toxicity of primaquine in Caucasians. J Am Med Assoc 1952;149:1563-8
2. FDA U. The critical path initiative: Report on Key Achievements in 2009. 2010.Available from: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/UCM221651.pdf [Cited 11 October 2010]
3. FDA U. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. 2010. Available from: http://www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ucm083378.htm [Cited 11 October 2010]
4. Yaeger R, Avila-Bront A, Abdul K, et al. Comparing genetic ancestry and self-described race in African Americans born in the United States and in Africa. Cancer Epidemiol Biomarkers Prev 2008;17:1329-38
5. Zdanowicz. Concepts in Pharmacogenomics. American Society of Health-System Pharmacists; Bethesda, MD; 2010
6. Nelson D. The Cytochrome P450 Homepage. 2009.August14 2009.Available from: http://drnelson. uthsc.edu/human.P450.table.html [Cited 29 August 2010]
7. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58:871-85 (Pubitemid 43967103)
8. Preissner S, Kroll K, Dunkel M, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2009;38:D237-43
9. Zhou H, Tong Z, McLeod JF. "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 2004;44:120-34 (Pubitemid 38114310)
10. Ingelman-Sundberg M, Daly AK, Nebert DW. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. 2010.Available from: http://www. cypalleles.ki.se/[Cited 29 August 2010] . Database for major CYP450 alleles.
11. Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008;9:625-37 (Pubitemid 351803920)
12. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89-295
13. Aklillu E, Carrillo JA, Makonnen E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003;64:659-69 (Pubitemid 37048569)
14. Han XM, Ouyang DS, Chen XP, et al. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 2002;54:540-3
15. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C- > A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9 (Pubitemid 29161279)
16. Ingelman-Sundberg M, Sim SC, Nebert DW. Coffee, myocardial infarction, and CYP nomenclature. Jama 2006;296:764-5.author reply 65-6 (Pubitemid 44223097)
17. Cornelis MC, El-Sohemy A, Kabagambe EK, et al. Coffee, CYP1A2 genotype, and risk of myocardial infarction. Jama 2006;295:1135-41 (Pubitemid 43352342)
18. Gentile G, Borro M, Lala N, et al. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010;11:431-5
19. Laika B, Leucht S, Heres S, et al. Pharmacogenetics and olanzapine treatment: CYP1A2 1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010;10:20-9
20. Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008;64:871-6
21. Mo SL, Liu YH, Duan W, et al. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 2009;10:730-53
22. Garcia-Martin E, Martinez C, Ladero JM, et al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10:29-40
23. Limdi N, Goldstein J, Blaisdell J, et al. Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Per Med 2007;4:157-69 (Pubitemid 46845895)
24. Scott SA, Jaremko M, Lubitz SA, et al. CYP2C9 8 is prevalent among African- Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009;10:1243-55
25. Speed WC, Kang SP, Tuck DP, et al. Global variation in CYP2C8-CYP2C9 functional haplotypes. Pharmacogenomics J 2009;9:283-90
26. Suarez-Kurtz G, Genro JP, de Moraes MO, et al. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 2010 December 21 online publication doi:10.1038/tpj.2010.89
27. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009;10:1489-510
28. Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007;7:362-5 (Pubitemid 47484774)
29. Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005;11:8097-104 (Pubitemid 41698753)
30. Bergmann TK, Brasch-Andersen C, Green H, et al. Impact of CYP2C8 3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011;11:113-20
31. Joerger M, Huitema AD, van den Bongard DH, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res 2006;12:2150-7
32. Kaspera R, Naraharisetti SB, Evangelista EA, et al. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol 2011;82:681-91
33. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010;278(2):165-88
34. Pedersen RS, Brasch-Andersen C, Sim SC, et al. Linkage disequilibrium between the CYP2C19 17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010;66:1199-205
35. Miura J, Obua C, Abbo C, et al. Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol 2009;65:319-20
36. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-13 (Pubitemid 43069582)
37. Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19 17. Br J Clin Pharmacol 2010;69:222-30
38. Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 2011;32:459-66
39. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806-11
40. Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008;1:620-7
41. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
42. Shuldiner AR, OConnell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama 2009;302:849-57
43. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009;30:916-22
44. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
45. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug- eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-34 (Pubitemid 351636443)
46. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588
47. Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2011;20:111-18
48. Park IH, Ro J, Park S, et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2012;131(2):455-61
49. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-50 (Pubitemid 32385908)
50. Cai WM, Nikoloff DM, Pan RM, et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J 2006;6:343-50 (Pubitemid 44480154)
51. Neafsey P, Ginsberg G, Hattis D, et al. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 2009;12:334-61
52. Sistonen J, Fuselli S, Palo JU, et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009;19:170-9
53. Westlind-Johnsson A, Hermann R, Huennemeyer A, et al. Identification and characterization of CYP3A4 20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 2006;79:339-49
54. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004;369:89-104 (Pubitemid 38161226)
55. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics 2009;10:1323-39
56. Liu YT, Hao HP, Liu CX, et al. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007;39:699-721
57. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243-72 (Pubitemid 38499965)
58. Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 2006;16:637-45 (Pubitemid 44223075)
59. Hart SN, Li Y, Nakamoto K, et al. Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab Pharmacokinet 2007;22:322-6
60. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008;18:339-48 (Pubitemid 351367527)
61. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011;57(11):1574-83
62. Thervet E, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005;6:37-47 (Pubitemid 40220669)
63. Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011;11:274-86
64. Thompson EE, Kuttab-Boulos H, Witonsky D, et al. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004;75:1059-69 (Pubitemid 39534403)
65. Diczfalusy U, Miura J, Roh HK, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3- hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008;18:201-8 (Pubitemid 351323234)
66. Yi B, Yang JY, Yang M. Past and future applications of CYP450-genetic polymorphisms for biomonitoring of environmental toxicants. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007;25:353-77 (Pubitemid 350135846)
67. Oscarson M, McLellan RA, Gullsten H, et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999;460:321-7 (Pubitemid 29495962)
68. Tricker AR. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. Toxicology 2003;183:151-73 (Pubitemid 36005395)
69. Mwenifumbo JC, Al Koudsi N, Ho MK, et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 2008;29:679-88 (Pubitemid 351614592)
70. Mwenifumbo JC, Zhou Q, Benowitz NL, et al. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics 2010;11:189-98
71. Moolchan ET, Franken FH, Jaszyna-Gasior M. Adolescent nicotine metabolism: ethnoracial differences among dependent smokers. Ethn Dis 2006;16:239-43 (Pubitemid 46959274)
72. Nakajima M, Kuroiwa Y, Yokoi T. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev 2002;34:865-77
73. Schoedel KA, Hoffmann EB, Rao Y, et al. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004;14:615-26 (Pubitemid 39281816)
74. McGraw JE Sr, Waller DP. Specific human CYP 450 isoform metabolism of a pentachlorobiphenyl (PCB-IUPAC# 101). Biochem Biophys Res Commun 2006;344:129-33
75. McGraw JE, Waller DP. The role of African American ethnicity and metabolism in sentinel polychlorinated biphenyl congener serum levels. Environ Toxicol Pharmacol 2009;27:54-61
76. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 2008;9:598-610
77. Ring HZ, Valdes AM, Nishita DM, et al. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenet Genomics 2007;17:1007-15 (Pubitemid 351339485)
78. Hofmann MH, Blievernicht JK, Klein K, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G > T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008;325:284-92 (Pubitemid 351439175)
79. Guan S, Huang M, Chan E, et al. Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur J Pharm Sci 2006;29:14-21 (Pubitemid 44279393)
80. Guan S, Huang M, Li X, et al. Intraand inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res 2006;23:1983-90
81. Puthanakit T, Tanpaiboon P, Aurpibul L, et al. Plasma efavirenz concentrations and the association with CYP2B6-516G > T polymorphism in HIV-infected Thai children. Antivir Ther 2009;14:315-20
82. Ramachandran G, Ramesh K, Hemanth Kumar AK, et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother 2009;63:841-3
83. Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 2009;65:355-63
84. Xu BY, Guo LP, Lee SS, et al. Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World J Gastroenterol 2007;13:2100-3
85. Rohrbacher M, Kirchhof A, Geisslinger G, et al. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics 2006;7:995-1002 (Pubitemid 44644779)
86. Zhou SF, Yang LP, Zhou ZW, et al. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. Aaps J 2009;11:481-94
87. Jaja C, Burke W, Thummel K, et al. Cytochrome p450 enzyme polymorphism frequency in indigenous and native American populations: a systematic review. Community Genet 2008;11:141-9 (Pubitemid 351465617)
88. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34(1-2):83-448 (Pubitemid 34311090)